当前位置:
首页
网刊
内毒素所致急性肺损伤治疗药物研究进展
内毒素所致急性肺损伤治疗药物研究进展
于子茹,杜冠华

中国医学科学院北京协和医学院药物研究所,北京市药物靶点研究与新药筛选重点实验室,北京 100050
Research progress of drugs for the treatment of LPS-induced acute lung injury
(Beijing Key Laboratory of Drug Targets Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

摘要参考文献相关文章

起始页:1510

摘要:[摘要] 急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)是临床病死率较高的疾病,其中,革兰氏阴性菌感染相关的ALI所占比例很大,致病因素主要为内毒素(LPS)。ALI发病机制错综复杂,目前仍无特效治疗药物。因此,针对LPS所致急性肺损伤的治疗药物研究受到广泛重视,围绕抗炎、抗凝血、改善肺水肿、抗氧化应激等方面的研究取得了新的进展,一些新型药物如表面活性物质、蛋白酶活性抑制剂、心房利钠肽等在临床上也已取得了一定成效。本文综述了LPS引起肺损伤的治疗药物研发进展,供抗ALI新药研发人员参考。

关键词:[关键词] 内毒素;急性肺损伤;急性呼吸窘迫综合征;治疗药物

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Acute lung injury/Acute respiratory distress syndrome (ALI/ARDS) is a kind of disease with high clinical mortality. Among them, the percentage of ALI associated with Gram-negative bacteria infection is very high, the main pathogenic factor of which is endotoxin (LPS). The pathogenesis of ALI is so complex that there is no specific treatment drugs. Therefore, the research on the treatment of LPS-induced acute lung injury has been paid more and more attention. And new progress has been made in the areas of anti-inflammatory, anticoagulant, improving pulmonary edema and anti-oxidative stress. Some new drugs such as surfactant, protease activity inhibitors and atrial natriuretic peptide has also achieved some clinical success. In this article, we reviewed treatment drugs of LPS-induced lung injury, which will provide references for the researchers to develop new anti-ALI drugs.

Key words:[Key words] endotoxin; acute lung injury; acute respiratory distress syndrome; therapeutic drugs

    [1] LI G, MALINCHOC M, CARTIN-CEBA R, et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in olmsted county, minnesota[J]. Am J Respir Crit Care Med, 2011, 183(1): 59-66.
    [2] MATTHAY MA, ZEMANS RL. The acute respiratory distress syndrome:pathogenesis and treatment[J]. Annu Rev Pathol, 2011,6(1): 147-163.
    [3] 李珊珊,赵光瑜,王忠慧. 水通道蛋白在急性肺损伤中的表达及调节[J].河北医药,2011,33(16): 2498-2500.
    [4] HOFSTRA JJ, JUFFERMANS NP, SCHULTZ MJ, et al. Pulmonary coagulopathy as a new target in lung injury—a review of available pre-clinical models[J]. Curr Med Chem, 2008,12(15): 588-595.
    [5] HADDAD JJ. Science review:Redox and oxygen sensitive transcription factors in the regulation of oxidant-mediated lung injury:role for nuclear facto-κB[J]. Crit Care, 2003,6(6): 47-54.
    [6] BRUICK RK, MCKNIGHT SI. Transcription enhanced:oxygen sensing gets a second wind

    [J]. Science, 2002, 295(5556): 807-808.
    [7] AIKAWA N, ISHIZAKA A, HIRASAWA H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study[J]. Pulm Pharmacol Ther, 2011, 24(5): 549-554.
    [8] MASTSUMOTO S, SHINGU C, KOGA H, et a1. The impact of oxidative stress levels on the clinical effectiveness of sivelestat in treating acute lung injury:an electron spin resonance study[J]. J Trauma, 2010, 68(4): 796-801.
    [9] O'NEAL HR JR, KOYAMA T, KOEHLER EA, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome[J]. Crit Care Med, 2011, 39(6): 1343-1350.
    [10] CRAIG TR, DUFFY MJ, SHYAMSUNDAR M, et al. A randomized clinical trial of hydroxymethylglutaryl—coenzyme a reductase inhibition for acute lung injury (The HARP Study)[J]. Am J Respir Crit Care Med, 2011, 183(5): 620-626
    [11] SONG C, SUZUKI S, KUBO H, et al. Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats[J]. Thorax, 2004, 59(1): 39-44.
    [12] LOONEY MR, NGUYEN JX, HU Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury[J]. J Clin Invest, 2009, 119(11): 3450-3461.
    [13] KOR DJ, ERLICH J, GONG MN, et al. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators. Association of prehospitalization aspirin therapy and acute lung injury:results of a multicenter international observational study of atrisk patients[J]. Crit Care Med, 2011, 39(11): 2393-2400.
    [14] BECHARA RI, PELAEZ A, PALACIO A, et al. Angiotensin II mediates glutathione depletion, transforming growth factor-beta1 expression, and epithelial barrier dysfunction in the alcoholic rat lung[J]. Am J Physiol Lung Cell Mol Physiol, 2005, 289(3): 363-370.
    [15] TRILLO-ALVAREZ CA, KASHYAP R, KOJICIC M, et al. Chronic use of angiotensin pathway inhibitors is associated with a decreased risk of acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2009,179(1):A4638.
    [16] WATKINS TR, LEMOS-FILHO L, DABBAGH O, et al. Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and clinical outcomesamong patients at-risk for acute lung injury[C]. Presented at American Thoracic Society 2011 International Conference, Vol 183 Meeting Abstracts.
    [17] WANG N, LIU X, ZHENG X, et al. Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model[J]. Int Immunopharmacol, 2013, 17(3): 799-807.
    [18] INOUE K, TAKANO H. Urinary trypsin inhibitor as a therapeutic option for endoxin-related inflammatory disorders[J]. Expert Opin Investig Drug, 2010, 19(4): 513-520.
    [19] GAO C, LI R, WANG S. Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator[J]. J Trauma Acute Care Surg, 2012, 72(1): 169-176.
    [20] RONGJU S, YANA LI, WEI CH, et al. Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respiratory distress syndrome[J]. Int J Clin Exp Pathol, 2015, 8(6): 7385-7390.
    [21] MITAKA C, HIRATA Y, NAGURA T, et al. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury[J]. Chest, 1998, 114(1): 223-228.
    [22] LUCE JM, MONTGOMERY AB, MARKS JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock[J]. Am Rev Respir Dis, 1988, 138(1): 62-68.
    [23] THOMPSON BT. Glucocorticoids and acute lung injury[J]. Crit Care Med, 2003, 31(4): 253-257.
    [24] PERKINS GD, MUAULEY DF, THICKETT DR, et al. The beta-agonist lung injury trial(BALTI):a randomized placebo-controlled clinical trial[J]. Am J Respir Crit Care Med, 2006, 173(3): 281-287.
    [25] GAO SMITH F, PERKINS GD, GATES S, et al. BALTI-2 study investigators. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2):a multicentre, randomised controlled trial[J]. Lancet, 2012, 379(9812): 229-235.
    [26] AIKAWA N, KAWASAKI Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome[J]. Ther Clin Risk Manag. 2014,5(10): 621-629.
    [27] MULLER HC, HELLWIG K, ROSSEAU S, et al. Simvastatin attenuates ventilator-induced lung injury in mice[J]. Crit Care, 2010, 14(4): R143.
    [28] MCAULEY DF, LAFFEY JG, O'KANE CM, et al. Simvastatin in the acute respiratory distress syndrome[J]. N Engl J Med, 2016, 375(20):2010.
    [29] TRUWIT JD, BERNARD GR, STEINGRUB J, et al. National heart, lung, and blood institute ARDS clinical trials network. rosuvastatin for sepsis-associated acute respiratory distress syndrome[J]. N Engl J Med, 2014, 370(23): 2191-2200.
    [30] BELLINGAN G, MAKSIMOW M, HOWELL DC, et al. The effect of intravenous interferonbata-1α(FP-1201)on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study[J]. Lancet Respir Med, 2014, 2(2): 98-107.
    [31] DEVECI F, MUZ MH, LLHAN N, et al. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma[J]. Respirology, 2008, 13(4): 488-497.
    [32] HAITSMA JJ, PAPADAKOS PJ, LACHMANN B. Surfactant therapy for acute lung injury/acute respiratory distress syndrome[J]. Curr Opin Crit Care, 2004, 10(1): 18-22.
    [33] PAOLA RD, CUZZOCREA S. Peroxisome proliferator-activated receptors and acute lung injury[J]. PPAR Res, 2007, 2007: 63745.
    [34] SCHAEFER MB, POSE A, OTT J, et al. Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury[J]. Eur Respir J, 2008, 32(5): 1344-1353.
    [35] LIU D, ZENG BX, ZHANG SH, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats[J]. Crit Care Med, 2005, 33(10): 2309-2316.
    [36] SUGA M, IYONAGA K, OKAMOTO T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2000, 162(5): 1949-1956.
    [37] FLIGIEL SE, STANDIFORD T, FLIGIEL HM, et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury[J]. Hum Pathol, 2006, 37(4): 422-430.
    [38] 陈向军, 马李杰, 侯绍杰,等. 白藜芦醇对脂多糖诱导的急性肺损伤的保护作用[J]. 中华肺部疾病杂志, 2013, 6(1): 13-16.
    [39] GONG MN, BAJWA EK, THOMPSON BT, et al. Use of ACE inhibitors and development and outcome in ARDS[J]. Am J Respir Crit Care Med, 2009, 179:A5095.
    [40] SPIETH PM, ZHANG H. Pharmacological therapies for acute respiratory distress syndrome[J]. Curr Opin Crit Care, 2014, 20(1): 113-121.
    [41] ABRAHAM E, REINHART K, OPAL S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis:a randomized controlled trial[J].JAMA, 2003, 290(2): 238-247.
    [42] CHU X, SONG K, XU K, et al. Ceftiofur attenuates lipopolysaccharide-induced acute lung injury[J]. Int Immunopharmacol, 2010, 10(5): 600-604.
    [43] HORAN GS, WOOD S, ONA V, et al. Partial inhibition of integrin alpha (v)beta6 prevents pulmonary fibrosis without exacerbating inflammation[J]. Am J Respir Crit Care Med, 2008, 177(1): 56-65.